866-997-4948(US-Canada Toll Free)

AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published By :

Global Markets Direct

Published Date : Apr 2015

Category :

Pharmaceutical

No. of Pages : 63


Global Markets Directs, AVEO Pharmaceuticals, Inc. Product Pipeline Review 2015, provides an overview of the AVEO Pharmaceuticals, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AVEO Pharmaceuticals, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides brief overview of AVEO Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AVEO Pharmaceuticals, Inc.s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement 
  • Latest news and deals relating to the AVEO Pharmaceuticals, Inc.s pipeline products
Reasons to buy
  • Evaluate AVEO Pharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AVEO Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AVEO Pharmaceuticals, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AVEO Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AVEO Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AVEO Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
AVEO Pharmaceuticals, Inc. Snapshot 6
AVEO Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
AVEO Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
AVEO Pharmaceuticals, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
AVEO Pharmaceuticals, Inc. - Pipeline Products Glance 16
AVEO Pharmaceuticals, Inc. - Late Stage Pipeline Products 16
Filing rejected/Withdrawn Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
AVEO Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
AVEO Pharmaceuticals, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
AVEO Pharmaceuticals, Inc. - Drug Profiles 22
tivozanib 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ficlatuzumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AV-203 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AV-380 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AV-232 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
GP-369 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AV-370 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody to Antagonize FGFR1 for Cancer 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody to Antagonize FGFR4 for Cancer 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody to Target Notch2 for Cancer 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody to Target Notch3 for Cancer 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody to Target Notch4 for Cancer 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AVEO Pharmaceuticals, Inc. - Pipeline Analysis 38
AVEO Pharmaceuticals, Inc. - Pipeline Products by Target 38
AVEO Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 40
AVEO Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 41
AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 42
AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates 44
AVEO Pharmaceuticals, Inc. - Dormant Projects 52
AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products 53
Discontinued Pipeline Product Profiles 53
AV-412 53
tivozanib 53
AVEO Pharmaceuticals, Inc. - Company Statement 54
AVEO Pharmaceuticals, Inc. - Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61

Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Table


AVEO Pharmaceuticals, Inc., Key Information 6
AVEO Pharmaceuticals, Inc., Key Facts 6
AVEO Pharmaceuticals, Inc. - Pipeline by Indication, 2015 8
AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 10
AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 11
AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015 12
AVEO Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 13
AVEO Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015 14
AVEO Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15
AVEO Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2015 16
AVEO Pharmaceuticals, Inc. - Phase III, 2015 17
AVEO Pharmaceuticals, Inc. - Phase II, 2015 18
AVEO Pharmaceuticals, Inc. - Phase I, 2015 19
AVEO Pharmaceuticals, Inc. - Preclinical, 2015 20
AVEO Pharmaceuticals, Inc. - Discovery, 2015 21
AVEO Pharmaceuticals, Inc. - Pipeline by Target, 2015 39
AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 40
AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 41
AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 43
AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 44
AVEO Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 52
AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 53
AVEO Pharmaceuticals, Inc., Subsidiaries 61

List of Chart


AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 8
AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 10
AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 11
AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015 12
AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 38
AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015 40
AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 41
AVEO Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *